Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

406

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

April 21, 2014

Study Completion Date

August 30, 2022

Conditions
Breast CancerCarcinoma of the Breast
Interventions
DRUG

Paclitaxel

Every week for 12 weeks

DRUG

Trastuzumab

Once a week for twelve weeks Then once a week or once every three weeks for 40 weeks

Trial Locations (20)

10021

Memorial Sloan Kettering Cancer Center, New York

10065

Weill Cornell Medical College, New York

11042

North Shore LIJ Health System Monter Cancer Center, Lake Success

21231

John Hopkins University, Baltimore

27599

University of North Carolina at Chapel Hill, Chapel Hill

27710

Duke Comprehensive Cancer Center, Durham

37203

Tennessee Oncology, Nashville

44195

Case Western University, Cleveland

46202

Indiana University, Indianapolis

60153

Loyola University Medical Center, Maywood

63110

Washington University, St Louis

94115

University of California-San Francisco, San Francisco

02114

Massachusetts General Hospital, Boston

02115

Beth Israel Deaconess Medical Center, Boston

02130

Dana-Farber at Faulkner Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

02601

Cape Cod Healthcare, Hyannis

01854

Lowell General Hospital, Lowell

01960

North Shore Medical Center, Peabody

05401

University of Vermont Cancer Center, Burlington

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

Genentech, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER